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Background: The Scottish Naloxone Programme aims to reduce Scotland’s high number of drug-related deaths
(DRDs) caused by opiate overdose. It is currently implemented through specialist drug services but General
Practitioners (GPs) are likely to have contact with drug using patients and their families and are therefore in an ideal
position to direct them to naloxone schemes, or provide it themselves. This research gathered baseline data on
GP’s knowledge of and willingness to be involved in DRD prevention, including naloxone administration, prior to
the implementation of primary care based delivery.
Methods: Mixed methods were used comprising a quantitative, postal survey and qualitative telephone interviews.
A questionnaire was sent to 500 GPs across Scotland. An initial mailing was followed by a reminder. A shortened
questionnaire containing seven key questions was posted as a final reminder. Telephone interviews were
conducted with 17 GPs covering a range of demographic characteristics and drug user experience.
Results: A response rate of 55% (240/439) was achieved. There was some awareness of the naloxone programme
but little involvement (3.3%), 9% currently provided routine overdose prevention, there was little involvement in
displaying overdose prevention information (<20%). Knowledge of DRD risk was mixed. There was tentative
willingness to be involved in naloxone prescribing with half of respondents willing to provide this to drug users or
friends/family. However half were uncertain GP based naloxone provision was essential to reduce DRDs.
Factors enabling naloxone distribution were: evidence of effectiveness, appropriate training, and adding to the local
formulary. Interviewees had limited awareness of what naloxone distribution in primary care may involve and
considered naloxone supply as a specialist service rather than a core GP role. Wider attitudinal barriers to
involvement with this group were expressed.
Conclusions: There was poor awareness of the Scottish National Naloxone Programme in participants. Results
indicated GPs did not currently feel sufficiently skilled or knowledgeable to be involved in naloxone provision.
Appropriate training was identified as a key requirement.* Correspondence: c.i.math@abdn.ac.uk
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In Europe there were an estimated 70,000 drug overdose
deaths in 2000-2010 [1]. Scotland has one of the highest
rates of Drug Related Deaths (DRDs) in Europe [2]. DRD
in Scotland have increased since 1997 and in 2011 there
were over 500, one per 10,000 of Scotland’s population.
The majority of these deaths involved opiates, usually by
injection and concurrent use of benzodiazepines and/or
alcohol [3]. Risk factors include a long history of drug use,
recent release from prison, psychological stress and home-
lessness [4]. One intervention that has shown potential ef-
fectiveness and cost-effectiveness is take-home naloxone
(THN) [5].
Naloxone is a short acting antagonist that temporarily
reverses the effects of an opiate overdose, generally ad-
ministered intra-muscularly. A number of successful
projects supplying THN to injecting drug users and their
families/friends have been conducted nationally and glo-
bally [6-9]. Across Europe just five countries have some
form of naloxone distribution (Denmark, Germany, Italy,
Romania and the United Kingdom) but this may still be
on a small scale [1]. Scotland and Wales are the only
countries with national programmes. Naloxone provision
through carers and families has been piloted in England
through the National Treatment Agency [10]. A full
programme across England has not yet been launched.
Many other countries are developing pilots e.g. Ireland.
The Scottish National Naloxone Programme (hereafter
‘the naloxone programme’) was launched in 2010 and
aims to reduce the high number of DRDs quantified in
the most recent National Records [11]. A national
programme of training and awareness is provided to
support local services delivering THN to those at risk.
Each NHS area has a named lead officer, responsible for
coordinating delivery at local level. Training aims to
raise awareness of overdose risk as well as equipping
drug users and family members with Basic Life Support
(BLS) skills including naloxone administration [12]. Dur-
ing 2011-12, 2730 naloxone packs were supplied in
Scotland; 87% to individuals, 11% to service workers and
2% to friends and family of those at risk [13]. A full
THN needs assessment is documented elsewhere [7].
Naloxone is currently largely distributed through spe-
cialist drug services in the UK; however the engagement
of general practitioners (GPs) is essential to maximise
reach. Almost all individuals in the UK are registered with
a GP and some drug users may not have access to or wish
to use a specialist service. GPs have a particularly import-
ant role to play in reducing DRD given that they are the
second most common service, after Statutory Addiction
Services, with which DRD victims were in contact prior to
their death [14]. The potential involvement of GPs in
DRD prevention is not a new concept although GPs’ in-
volvement in managing drug users has recently decreasedin Scotland [15] which may have impacted on involvement
in DRD prevention work.
The “enhanced service” contractual arrangements for
substance misuse outline the service level to be provided
for substance misuse management by some GPs. Not all
GPs manage drug dependence routinely, but all GPs
should provide general medical care. Co-morbidity in
DRDs is common with over half of cases having a psy-
chiatric condition and almost half having an alcohol
problem [5]. Analysis of the causes of premature mortal-
ity in a cohort of drug users in Edinburgh found a range
of co-morbid conditions including HIV, hepatitis C in-
duced liver disease, kidney failure, respiratory disease
and cardio-vascular disease [16]. Thus, drug users may
consult their GP even if not in relation to illicit drug
problems.
GPs are in an ideal position to either direct patients
towards naloxone administration training and supply or
to provide it themselves. Additionally, GPs may see fam-
ily members who could potentially administer naloxone
[17]. GP based DRD prevention including naloxone dis-
tribution has not previously been documented or evalu-
ated in the international literature. This research aimed
to gather baseline data on GP’s current understanding,
knowledge and willingness to be involved in DRD pre-
vention, including naloxone administration, prior to
considering the implementation of primary care based
delivery.
Methods
The study used mixed methods comprising a quantita-
tive postal survey and qualitative telephone interviews.
Both strands ran concurrently and results are presented
separately below.
Quantitative postal survey
A four page questionnaire was developed following fa-
miliarisation with the literature and was pre-piloted with
a sample of academic GPs. The length of questionnaire
was the main issue raised by pilot participants, but it
was deemed difficult to further reduce without losing
important content.
The questionnaire covered:
 Current GP practice relating to drug misuse
generally;
 GP knowledge of DRDs and perception of risk
factors [12];
 GP awareness, attitudes and involvement in the
naloxone programme including factors that might
influence involvement and views on different models
of delivery;
 GP training;
 Demographics.
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national database listing all GPs in Scotland [18], and
stratified by Health Board area to ensure geographical
spread. Twenty GPs were used in the pilot sample and
500 for the main distribution. Prior to the main question-
naire mailing, a letter from the Director of Public Health
Sciences at NHS Health Scotland was sent to potential
participants, endorsing the naloxone programme and en-
couraging response to the questionnaire which followed
approximately one week later. Such pre-notification is
considered effective at increasing response rates [19].
The main distribution was mailed in August 2012; a
postal reminder was sent two weeks later. Following this,
telephone reminder calls were made to managers of
practices in which potential participants worked to en-
sure that the named GP was still in the practice and that
the questionnaire had been received. A number of GPs
had left, retired, or were on sickness or maternity leave.
Since the response remained low, a one-page version of
the questionnaire was sent as a final reminder to non-
responders, containing only key questions.
Data analysis
Data were entered into an SPSS V20 database. Simple
descriptive statistics (frequencies and distributions) were
calculated and cross-tabulations using chi-squared tests
were conducted for demographic variables (gender, years
of GP experience, specialist training level, geographical
location of practice and whether or not participants were
currently treating drug misusers) against perceptions of
risk factors in relation to DRDs and involvement in and
knowledge of the national programme.
Qualitative interview study
Telephone interviews were conducted to elicit GPs’
views on how to engage the GP community in the nalox-
one programme. A short topic guide was developed,
seeking views on GP involvement, barriers and enablers
to involvement as well as experience of naloxone use
and drug misuse treatment generally.
A purposive sample was used to cover a range of differ-
ent levels of experience with patients who have drug
problems generally and naloxone specifically. GPs were
recruited through the Royal College of General Practi-
tioners (RCGP), Scottish Prison Service, Scottish Primary
Care Research Network and NHS Health Scotland; those
identified as potential interviewees were contacted by
post or e-mail, sent an invitation and information sheet,
and an interview time arranged.
Telephone interviews lasted 15-20 minutes and were
transcribed verbatim. A basic thematic analysis was
undertaken. Emergent themes were identified by one re-
searcher and cross checked by a second. The range of
views and experiences under those themes presented.Emergent themes were both topic specific and across
topics.
Ethics
Ethical approval was granted by the College Ethical
Review Board of the College of Life Sciences at the
University of Aberdeen. Consent for questionnaire par-
ticipation was implied. Written consent was obtained for
interview participants.
Results
Quantitative results
A total of 183/439 GPs contacted responded to the long
questionnaire. An additional 57 (previous non-responders)
returned the short questionnaire giving an overall re-
sponse rate of 55% for the key questions. Thus the number
of respondents was either 183 or 240.
Of the responding GP’s, there was an even gender
split, under half (47%) currently treated drug misusers
and most had not undertaken any recognised form of
specialist training (Table 1); those who had such training
also tended to be those treating (77% some training vs
34% no training Pearson Chi-Squared, p < 0.001, data
not shown). Only 4% had any specific training on the
prevention of DRDs, although the majority expressed an
interest in receiving training.
While most of the responding GPs were town-based,
proportionately more of the city GPs treated drug
misuse, 82% compared to 29-49% elsewhere (Pearson
Chi-Squared, p < 0.001, data not shown).
43% of respondents did not know how many Drug
Related Deaths (DRDs) occur in Scotland and only 12%
knew that the actual figure was currently around 500/
year. Responses to questions testing knowledge of DRDs
are described in Table 2.
Knowledge of risk factors for DRD is shown in Table 2.
While this generally appears high, it is notable that 60%
agreed that those aged under 24 years are at higher risk:
not a ‘real’ risk factor. While ‘psychological stress’ was
ranked lower than the major risk factors it was consid-
ered important by 82% of female GPs responding, com-
pared to 60% of their male counterparts (Continuity
Correction Chi-Squared, p = 0.002, n = 182) indicating a
gender bias.
9% of respondents provided some form of overdose
prevention. Just over half had heard of the naloxone
programme. However, most did not display information,
did not know who their local naloxone lead officer was
and were not involved with the national programme
(Table 3). Around half knew where to refer drug users
for naloxone and almost half were prepared to pre-
scribe/explain naloxone to patients and to patients’ fam-
ilies/friends. Those not prepared to prescribe stated that
their main concern was insufficient training/knowledge/
Table 1 Questionnaire respondent characteristics
Male: 108/237 (45.6%)
Currently treat drug misusers: 113/239 (47.3%)
GP experience: (years) n = 181 ≤4 5-9 10-19 20+
23 (12.6%) 22 (12.0%) 6 2 (33.9%) 76 (41.5%)
Location ‡n = 236 City Centre: Suburban: Town: Rural:
54 (22.9%) 39 (16.5%) 101 (42.8%) 42 (17.8%)
Specialist training: † n = 181 None: Some: More:
127 (70.2%) 29 (16.0%) 25 (13.8%)
†None: none recognised; Some: RCGP 1 or local specialist service-run training programmes.
More: RCGP 2 or other Credited Post graduate course.
Town: 4,000-90,000 inhabitants; Rural: <4,000 inhabitants.
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patients, 91% would also prescribe/explain to family/
friends: a significant trend response (Chi-Squared for
Trend, p < 0.001, data not shown) such that their re-
sponse to one would reliably determine the other.
Training influenced willingness to prescribe and explain
naloxone to a patient. While 99 respondents (45%) were
willing, when broken down into level of training, signifi-
cantly more (72%) with the highest training levels were
prepared to prescribe naloxone to patients (p = 0.026).
There was no significant association between current
treatment of drug misusers and willingness to prescribe
naloxone to patients or family friends (p = 0.70 and
p = 0.85 respectively).
Factors to enable extending the naloxone programme
into primary care are described in Table 4. That the
programme should be evidence-based was considered
very important by most respondents, followed by ‘GP ap-
propriate training’. Conversely, being within the Quality
and Outcome Framework (QOF – the system of per-
formance indicators through which GPs are substantially
remunerated) was regarded as ‘not important’.Table 2 Drug related deaths (DRDs) risk factors
DRD risk factors* (n = 183) %
People who inject 91.3
People recently released from prison 86.9
People who take alcohol with other drugs 86.9
People who take benzodiazepines with other drugs 74.9
Homeless people 74.9
Those newly started on opiate replacement 71.6
People who’ve had additional psychological stress 70.5
People who are under 24 years old † 60.7
People who’ve recently been on a detox programme 59.0
People who’ve used illicit drug for a long time 56.8
Do you provide overdose prevention: n = 177 9.0%
*Ordered as per proportion, not as in questionnaire.
†Note: not an actual risk factor.Most GPs who expressed a choice selected the model
where GPs only prescribe and others deliver basic life sup-
port (BLS) and naloxone training 158/170 (92.9%). Of these,
69% felt someone else should deliver this training (Commu-
nity Psychiatric Nurse/Specialist Nurse/key worker). There
were mixed views on how such an intervention should be
delivered i.e. one-to-one or small groups, but more thought
take-home naloxone (THN) intervention sessions should
be 20-30 minutes rather than brief (<10 minutes).
Once naloxone has been prescribed, debriefing and re-
supply was seen by 55% of the GPs to be their responsibil-
ity. A further 39% cited ‘others’, mainly outside services
such as shared-care clinics, substance misuse services or
psychiatric nurses.
Views about the impact of naloxone distribution are
shown in Table 5. Half of respondents were uncertain
that general practice based distribution was essential to
reduce DRDs.
Qualitative findings
25 GPs not in the survey sample were approached for an
interview: 17 agreed to participate, from a range ofTable 3 Involvement in the Scottish national naloxone
programme
Heard of the national
programme? †:
n = 240 Yes: 57.1%
Display/give out infomation on
Naloxone?
n = 181 Yes: 18.23%
Know local naloxone lead? n = 182 Yes: 8.2%
Involved with national
programme?
n = 181 Yes: 3.3%
Know where to refer for
naloxone?
n = 181 Yes: 55.2%
Prepared to prescribe & explain † n = 237 Yes: No: Unsure:
naloxone to patients at risk? 43.9% 22.4% 33.8%
Prepared to prescribe naloxone &
explain to family /friend?
n = 182 Yes: No: Unsure:
50.5% 22.0% 27.5%
†Included in the final short questionnaire reminder (n = 240).
Table 4 Importance of factors to extending the naloxone
programme (n = 240)
Factors* Very Somewhat Not n
important important important
Have supporting evidence 89.7% 9.5% 0.9% 232
GP appropriate training 82.8% 14.2% 3.0% 233
Must be on local formulary 67.2% 24.6% 8.2% 232
Practice nurses appropriate
training
52.3% 30.6% 17.1% 222
GP paid for service 43.5% 39.7% 16.8% 232
Should be included in the
QOF†
14.7% 28.4% 56.9% 225
†QOF: Quality and outcome Framework.
*Ordering with respect to importance.
Bold% indicates highest ranked within that factor.
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view and 16 were conducted by telephone. Most inter-
viewees had some experience with substance misuse
patients.
Analysis identified the topic-based themes which mir-
rored the topics in the interview guide: experience of na-
loxone, willingness to supply naloxone, opportunistic
supply, models of delivery in practice, and barriers.
In addition, there were emergent themes across topics,
considered in the discussion. These were: lack of know-
ledge, ‘typecasting’, ‘off-their-radar’ and negative attitudes.
Experience of naloxone
There was little experience of using naloxone for opiate
overdose. Some had heard of the naloxone programme
but were unaware of details. One interviewee had used na-
loxone while working in a hospital emergency department,
another had been involved in a pilot study of THN. Others
kept it in their medical bag for emergency use, one has pa-
tients involved in the naloxone programme through the
shared-care clinic. One practice was previously involved in
the nurse-led naloxone programme which stopped when
the nurse left.
One practice kept naloxone for emergencies; however,
it was not routinely used and never prescribed to takeTable 5 Attitudes (%) concerning the distribution of naloxone
Statements
I believe General Practice based distribution of naloxone is essential to reduc
related deaths.
I am concerned that giving injecting drug users naloxone might encourage
injecting practices.
I am worried that if naloxone is administered by a peer to an injecting drug
they might not phone for an ambulance.
I believe the National Naloxone Programme is an important use of NHS reso
I feel confident in identifying and addressing overdose risks.
Bold% indicates highest proportion within that Statement.home. Another had patients involved in the naloxone
programme, and would participate in the prescribing
and speaking to family/peers.
Another interviewee reported that naloxone training
was provided by their psychiatric nurse, one occasionally
prescribed naloxone on the recommendation of a spe-
cialist nurse or to a drug user who had been prescribed
it elsewhere and needed re-supply. Prison GPs were fa-
miliar with naloxone and its availability would be men-
tioned at discharge but no specific information provided.
One interviewee familiar with naloxone has discussed
it with patients, two of whom expressed an interest.
However, he hesitated to prescribe it without having had
proper training. Several interviewees had never heard
about the naloxone programme.
Willingness to participate in the naloxone programme
Most interviewees were in favour of participation. A
range of motivations were evident with some uncertainty
surrounding scope and delivery. Some did not see the
need in their own practice as there were few/no cur-
rently registered drug users:
‘…we don’t need it, but if we had drug misusers, we
would refer them to the drug misuse service.’
Several interviewees commented that this would have
to be discussed with other GPs in the practice as some-
times there was a lack of support from colleagues. One
in particular had offered to arrange an interview with his
partner who opposed treating drug users and naloxone;
however the partner was unwilling to talk about his
negative views. Another practice provided naloxone
training through drug services. Whilst interested, this
interviewee did not think that general practice prescrib-
ing was required:
‘We already participate to an extent, in that we are
supporting patients in accessing the training …I don’t
see ourselves prescribing it directly to people, there
doesn’t seem to be any particular need…’(n = 183)
n Strongly
agree
Agree Uncertain Disagree Strongly
disagree
e drug 182 6.6% 19.8% 49.5% 14.3% 9.9%
riskier 183 5.5% 20.9% 24.7% 37.9% 11.0%
user 181 9.9% 40.9% 28.7% 19.9% 0.6%
urces. 181 5.5% 40.3% 44.8% 6.6% 2.8%
182 2.7% 21.4% 37.4% 34.1% 4.4%
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there was a financial benefit:
‘If the financial aspects were favourable......then the
motivation for being involved with a heavy time
commitment group of patients, might…be attractive.’
Another interviewee supported the programme after
experiencing a DRD which may have been preventable
had naloxone been available; others would like to receive
evidence of clinical benefit before introducing naloxone
prescribing. One prison interviewee reported a critical
incident that influenced his willingness to prescribe:
‘…a prisoner broke into our drug cupboard room and
quite a few people were taking …medications…limited
amount of naloxone was stocked and we did run out
of naloxone….’
Opportunistic naloxone
Interviewees were asked how they might deal with a pa-
tient who presented for an appointment unrelated to
substance misuse, but during the consultation, the GP
suspected that they were using drugs and may be at risk
of overdose.
Most interviewees did not feel that they have the skills
or knowledge to deal with such a situation comfortably
and would refer the patient to a substance misuse facil-
ity; others would approach the situation, deal with clin-
ical needs, possibly discuss methadone prescribing and
then refer to a substance misuse clinic where they can
get naloxone:
‘If I knew exactly what to do, I would treat them.....’
‘…may refer them onto more specialist services, or
the practice substance misuse clinic.’
One interviewee reported that all patients are routinely
asked about drug use at the time of joining the practice;
therefore it is unlikely that drug problems would be
picked up by coincidence. If a patient has ever used
drugs, this will be discussed and if they are regular drug
users they will be encouraged to have their own THN
supply. Another interviewee reported that if a patient
appeared to be a drug user but has come for something
else, he will ask outright if they are taking heroin. Others
would assess if the patient wants to change their drug
using behaviour; if they had no desire to do so, they
would give very brief advice. If they indicated that they
wanted to change, or get help, they would be referred to
drug treatment teams for initial assessment.
Models of delivery in practice
Interviewees were asked how they could envisage the na-
loxone programme to be best delivered in general prac-
tice. Responses fell into two categories:A specialised substance misuse service
Existing models of shared-care programmes and sub-
stance misuse services were sufficient and there was no
need to change this:
‘The way that it’s done just now…between GP and
drug support workers…it would be reasonable to be
doing it along the same lines. .’
‘…best mode of delivery is to convey to patients that
it is through addiction support…then the kit is
provided by the local pharmacy....not delivered
through our practice.’
Non-specialist (GP, nurse or specialist worker)
Several interviewees felt that any clinician or specialist
worker could deliver this service, as long as it is the per-
son who has the most contact with the patient. Often
this will be a specialist nurse who can more readily as-
sess what is required. Only two interviewees had very
strong views that the programme should be GP and not
nurse led:
‘…it’s not going to be nurse led…we may take advice
of substance misuse nurse, but it’s going to be GP led.’
‘I think from experience of this type of problem, and
this type of patient presentation, I can see the benefits
of a more specialist role…a GP with a specialist
interest…’
Another suggestion was to invite drug users for longer
appointments or in a group with families/peers. If nalox-
one is requested, further information and a referral
would be offered.
One interviewee works with a psychiatric nurse to
treat drug users but this does not include naloxone
provision. He believed if it is to be implemented:
‘…it should be everybody, if you are going to do these
things with drug users, it has to be opportunistic, it
has to be linked in with other services, and you have
to take the opportunity when you get it..’
Similarly another interviewee commented that it
should be provided through both general practice and
specialist services; otherwise a group of patients may
be missed.
Barriers to naloxone provision
Not part of the GP package
Several interviewees mentioned that substance misuse is
not part of the core GP contract; overdose prevention
information and naloxone training and supply should be
part of an enhanced (optional) service contract:
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work as it is.’
‘…there are no additional resources to prescribe
naloxone, or to talk to patients about naloxone, it’s
not part of the enhanced service contract…’
Education
It may be difficult to engage GPs to attend educational
sessions for several reasons:
‘…fear of looking like an idiot.’
‘…it may ‘take up too much time’
‘GPs may work in an area with low drug misuse and
they don’t feel they have the skills.’
Others were concerned about lack of appropriate train-
ing and a reluctance to prescribe an injectable drug to a:
‘…chaotic drug user.’
They will need somebody else to administer it which
may be difficult as drug users often have a limited and
chaotic social circle:
‘…a bit pointless, I’m prescribing it for you, but you
are not going to be the person to administer it.’
The need for GPs to be educated and convinced that
this is something important to do was noted by others.
On-site presentations were suggested to reach the full
target group.
Safety net
A significant concern was that if drug users have access
to naloxone, it may encourage those who were previ-
ously frightened to take heroin; it may also tempt
current heroin users to increase the amount as they now
have perceived safety net:
‘People may think it is safe as long as I’ve got the
naloxone there.’
There was concern that when the effect of naloxone
wears off and the ambulance has not arrived, a further
dose may be needed and still result in a fatal overdose:
‘…I think there would be a concern that…somebody
might get a single dose of naloxone and an ambulance
not be phoned…it could potentially then be
dangerous.’
Reluctance to treat drug users
Practices not prescribing methadone may consider that
engagement with the naloxone programme is too close tobecoming involved with drug users. This opinion was
voiced by several interviewees; however, one said that even
if GPs do not want to treat drug users, they can still pro-
vide a possible life saving treatment. Pre-conceived charac-
teristics of drug users were another barrier:
‘…an individual GP prejudice…they may not want to
be involved with that type of patient…’
‘Not wanting to treat drug users....it’s got to do with
their own attitude....which is pretty shameful, but
there you go.’
Not all interviewees were negative: one comment from
an interviewee sympathetic to naloxone prescribing
noted:
‘…at the end of the day, they are all somebody’s
children… it’s very important that GP’s are pro-active
and sympathetic in helping…as much as possible.’
Discussion
The use of mixed methods in this study allowed both na-
tional representation and breadth of information alongside
in-depth interview data. The survey response rate was ini-
tially low, but boosted by the short questionnaire sent as a
third reminder. Generating a good response rate from GPs
for postal questionnaires is challenging. The final response
of 55% compares well with most recent GP survey re-
sponse rates in the UK [15].
The proportion of the survey respondents currently
treating drug users (47%) was comparable to a previous
survey in the same population (44%) [15], the level of
experience of the naloxone programme was very low
with only six individuals being involved.
Knowledge of the number of DRDs in Scotland was
surprisingly poor considering that there had been exten-
sive media coverage of the previous year’s DRD figure
just before the initial mailing [20]. GPs had low confi-
dence in identifying and addressing overdose risk (24%).
Almost two thirds of respondents had heard of the na-
tional programme, mostly from NHS communications.
NHS Scotland has thus had some impact in trying to
broaden awareness although few knew who their local
naloxone lead officer was or who provided naloxone
information.
There was uncertainty from survey and interview data
about whether general practice was a suitable place for
the national programme, although almost half were pre-
pared to prescribe naloxone and explain it to those at
risk (or family/friends); a relatively high proportion were
‘unsure’ indicating willingness if certain requirements
were fulfilled. It is nevertheless likely that GPs interested
in treating problem drug use may have been over-
represented in our sample.
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evident in interviews and centred on a lack of knowledge
and the belief that drug treatment is best managed
through specialist services; this was evidence of ‘type-
casting’ naloxone prescribing as a specialist service.
Half of respondents were uncertain whether general
practice based distribution of naloxone was essential to
reduce DRDs. This indicates the need for information
and ‘evidence’ to convince them that they have a role ra-
ther than leaving it to others; this was again echoed in
interviews.
Interview data also suggested that practices not treat-
ing drug users may consider that naloxone provision is
too close to becoming involved with this patient group.
Negative attitudes towards drug users indicate under-
lying attitudinal barriers which could be interpreted as
the stigmatisation using current definitions [21]. This is
linked to the other emerging themes of typecasting drug
misuse treatment as a specialist service. Some GP’s may
be keen to ‘offload’ what is perceived as a difficult group
to specialist services rather than considering the non-
specialist care that is also required; overdose prevention
may be part of this.
The existing literature on GPs attitudes to treating
drug users is old and our evidence suggests that atti-
tudes may not have changed over time. Training GPs in
drug misuse is known to change attitudes [22]; our data
support the view that those with more training are more
willing to provide naloxone to drug users although caus-
ality cannot be assumed. It was noted that the naloxone
programme could ‘easily’ be added to the substance mis-
use enhanced care package.
The main motivating factor in one GP was the experi-
ence of a potentially avoidable patient death. This find-
ing concurs with other evidence that experience of a
DRD on the caseload of staff does cause a grief-related
response [23]. Perhaps this type of experiential evidence
could be used to motivate others.
Two models of delivery in general practice were pre-
sented in the survey and the preferred one was where
GPs only prescribe and others deliver the training. There
was uncertainty about whether group or ‘one-to-one’ de-
livery was preferable, but most believed that the training
intervention should be 20-30 minutes. Those preferring
a brief intervention type model considered opportunistic
delivery preferable. Interviews specifically probed the
idea of opportunistic delivery; many perceived this as
unrealistic either because they know all their patients or
drug users are treated by specialist services.
It was raised in interviews that the intervention could be
provided by any health professional in contact with drug
users. Other models exist already e.g. pharmacy prescrib-
ing in which GPs refer people at risk to the pharmacy.
More generally, it was considered that reducing overdoserisk should be the priority; otherwise there could be an as-
sumption that someone else is addressing the issue.
Barriers to GP delivery of the Naloxone Programme
In May 2013, after data collection, a community pack of
naloxone was launched (Prenoxad Injection: naloxone
1 mg/1 ml solution) following the granting of a Medicines
Licence by the UK Government. This is the world’s first
licensed naloxone product for emergency use in non-
medical setting by appropriate individuals. It removes any
legal/licensing barriers to GP prescribing.
Concerns were expressed that drug users might actu-
ally engage in more risky practice by knowing naloxone
was available. However, in the survey just a quarter of
respondents agreed. The evidence indicates this concern
is not realised in practice which should be addressed in
any training. It was also suggested that drug users them-
selves are seen as not aware of their personal risk of a
DRD so they might not be receptive to overdose preven-
tion. There is some supportive literature around this
concept given that 94.5% of fatalities were considered to
be non-deliberate [24]. Rather than a barrier this is fur-
ther evidence supporting the need for THN.
Stigmatisation of drug users has been considered in
detail recently [21]; it has been acknowledged that health
professionals can stigmatise drug users and our findings
support that. Viewing drug misuse as a health issue ra-
ther than a criminal one may result in less stigmatisation
[21]. As one interviewee suggested emphasising the life-
saving nature of supplying THN could encourage GPs to
provide this intervention to people at risk.
Attitudinal and time barriers clearly exist and are diffi-
cult to address. Education and training may overcome
some attitudinal barriers but achieving attendance can
be challenging and training might need to be taken to
practices. There may however also be a need to work
with GPs who do not want to treat drug users or do not
feel they have the time. Opportunistic naloxone pre-
scribing with a brief intervention to those at risk could
be delivered without much commitment to further in-
volvement but only if these GPs were convinced it would
be sufficiently safe and could save lives.
Enablers
Training and the need for evidence supporting THN were
considered very important by the majority of question-
naire respondents; most did not think it should be part of
the core GP performance payment system, the Quality
and Outcomes Framework (QOF). This view may reflect a
reluctance to encourage all GPs to do something they may
not feel skilled to do or do not want to do.
The need for effective training of clinicians (not just
general practitioners) was also recognised in English
pilots of a cascading model of training in overdose
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essential features for training. There is a strong need for
information to have supporting evidence. As noted above
the need to emphasise to GPs the key message that nalox-
one is lifesaving. Training also needs to be delivered sensi-
tively: our interviews indicated that some GPs might feel
embarrassed by their lack of knowledge. Furthermore, it
should not be assumed that GPs have any level of know-
ledge of how to administer naloxone. Even those who are
used to working with drugs users have rarely been in-
volved in naloxone administration.
Policy implications
This research raised wider policy issues. Allowing specia-
lised GP services within the GP contract may have exacer-
bated non-participation of generalist GPs in caring for
drug users and lack of familiarity with the concept of pre-
ventive naloxone may have provided a justification among
some GPs for engaging with what could be interpreted as
provision of a new, unfunded, service. Drug users suffer
multi-morbidity and die prematurely from a range of
health conditions as well as DRDs [5] thus they need gen-
eral medical care as well as specialist drug treatment. Gen-
eral medical care may be underprovided and this issue
requires further assessment. There is evidence of stigma-
tisation of drug users by GPs in this study and other re-
search; in an analysis of ‘revolving door’ patients i.e. in
patients who had been removed from a practice list four
or more times, 84% were substance misusers [26].
The negative attitudes of some GPs may underpin the
lack of willingness to provide naloxone specifically but
may also underpin the lack of willingness to have any in-
volvement with drug users [21]. No recent published re-
search has considered whether GPs stigmatise drug
users as a patient group in this way although it is ac-
knowledged that the phenomenon exists [27].
Conclusions
There was minimal awareness among Scottish GPs of
the naloxone programme. Current levels of knowledge
and experience of DRD and naloxone use are low, and
information needs are high. GPs classify naloxone
provision as a specialist service and may therefore as-
sume it is not part of their remit. However, there were
signs that some GPs would be willing to be involved if
certain enablers were addressed, particularly appropriate
evidence-based training. Negative attitudes towards drug
users are a barrier to GP care of this patient group. It is
possible that changes to the contractual arrangements
for GPs may be required to achieve more widespread en-
gagement with the naloxone programme.Competing interests
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